MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

MDT

84.83

+1.33%↑

VEEV

231.93

+3.06%↑

A

107.72

+1.87%↑

WBA

10.97

+0.09%↑

CHE

581.87

+4%↑

Search

Akebia Therapeutics Inc

Deschisă

SectorSănătate

2.44 2.09

Rezumat

Modificarea prețului

24h

Curent

Minim

2.36

Maxim

2.47

Indicatori cheie

By Trading Economics

Venit

-2.8M

-23M

Vânzări

9.1M

46M

EPS

-0.1

Marjă de profit

-49.044

Angajați

181

EBITDA

-2.6M

-6.6M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+172.84% upside

Dividende

By Dow Jones

Următoarele câștiguri

8 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

128M

541M

Deschiderea anterioară

0.35

Închiderea anterioară

2.44

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Akebia Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 apr. 2025, 23:27 UTC

Top știri

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28 apr. 2025, 23:07 UTC

Top știri

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28 apr. 2025, 23:03 UTC

Câștiguri

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28 apr. 2025, 23:47 UTC

Market Talk

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28 apr. 2025, 23:17 UTC

Câștiguri

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28 apr. 2025, 23:17 UTC

Câștiguri

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28 apr. 2025, 23:13 UTC

Câștiguri

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28 apr. 2025, 23:13 UTC

Câștiguri

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28 apr. 2025, 23:13 UTC

Câștiguri

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28 apr. 2025, 23:13 UTC

Câștiguri

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28 apr. 2025, 23:08 UTC

Câștiguri

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28 apr. 2025, 23:08 UTC

Câștiguri

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28 apr. 2025, 23:08 UTC

Câștiguri

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28 apr. 2025, 23:04 UTC

Câștiguri

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28 apr. 2025, 23:04 UTC

Câștiguri

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28 apr. 2025, 23:04 UTC

Câștiguri

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28 apr. 2025, 23:04 UTC

Câștiguri

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28 apr. 2025, 23:00 UTC

Câștiguri

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28 apr. 2025, 23:00 UTC

Câștiguri

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28 apr. 2025, 23:00 UTC

Câștiguri

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28 apr. 2025, 23:00 UTC

Câștiguri

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28 apr. 2025, 22:57 UTC

Top știri

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28 apr. 2025, 22:55 UTC

Câștiguri

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28 apr. 2025, 22:55 UTC

Câștiguri

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28 apr. 2025, 22:55 UTC

Câștiguri

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28 apr. 2025, 22:52 UTC

Câștiguri

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28 apr. 2025, 22:52 UTC

Câștiguri

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28 apr. 2025, 22:52 UTC

Câștiguri

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28 apr. 2025, 22:52 UTC

Câștiguri

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28 apr. 2025, 22:46 UTC

Câștiguri

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Comparație

Modificare preț

Akebia Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

172.84% sus

Prognoză pe 12 luni

Medie 6.63 USD  172.84%

Maxim 7.5 USD

Minim 6 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAkebia Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.15 / N/ASuport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.